DEFC14A: Saba Capital Seeks to Expand ASA Gold and Precious Metals Board, Appoint Independent Director

Saba Capital is soliciting proxies to expand the board of ASA Gold and Precious Metals Limited and appoint an independent director, aiming to enhance shareholder value and address concerns over the company's governance.

Summary

• Saba Capital Management, L.P., along with Boaz R. Weinstein, is soliciting proxies from shareholders of ASA Gold and Precious Metals Limited for a special general meeting.
• The purpose of the meeting is to expand the Fund's board of directors from four to five members and to appoint Maryann Bruce as an independent director.
• Saba believes that Ms. Bruce's extensive experience in finance, mutual funds, and corporate governance would benefit all shareholders.
• Saba is seeking shareholder support to approve the board expansion (Proposal 1) and the appointment of the independent nominee (Proposal 2).
• As of April 28, 2025, the Participants may be deemed to beneficially own 3,253,837 Common Shares, including 1,913,658 Common Shares held in record name.
• The proposals will be decided upon by a simple majority of votes cast at the general meeting.
• Saba intends to deliver this Proxy Statement and the accompanying Form of GOLD Proxy Card to holders of at least the percentage of the Funds voting shares required under applicable law to approve each of the Proposals at the Special Meeting.

Sentiment

Score: 4

Explanation: The document is largely negative due to the ongoing dispute over the poison pill and the need for shareholder intervention. While the addition of an independent director is a potential positive, the overall tone is critical of the current board and management.

Positives

• The addition of an independent director with extensive experience in finance, mutual funds, and corporate governance could benefit the Fund.
• Saba Capital's efforts to address concerns over the company's governance may lead to improved shareholder value.
• The independent nominee was sourced by a third-party recruiter who Saba has never previously worked with, based on the needs of the Fund.
• The Independent Nominee is fully independent of both the Fund and Saba.

Negatives

• The Fund's board has repeatedly adopted poison pills, which a court has ruled violate the 40 Act.
• The Rights Plan Committee instituted a new Poison Pill even after and in blatant disregard of the Court ruling that such pills violate the 40 Act.
• The legacy directors have been responsible for spending millions of dollars of shareholder money to do so.
• The legacy directors have gone to great lengths, including by shielding their actions through committees formed only hours before the previous annual meeting, to prevent the new directors, who were just voted in by shareholders, from holding them to account and putting an end to the avalanche of legal expenses they are incurring in their fight to continue inflicting poison pills upon shareholders.

Risks

• The Fund's continued use of poison pills could deter potential acquirers and depress the stock price.
• The legal battle over the poison pills could be costly and time-consuming.
• There is no guarantee that the independent nominee will be elected or that her presence on the board will lead to improved performance.
• If the Board does not call the Special Meeting as it is required to do under Section 74(1) of the Bermuda Companies Act, Saba will need to convene the Special Meeting in accordance with Section 74(3) of the Bermuda Companies Act and the Fund will be required by Section 74(5) of the Bermuda Companies Act to bear the reasonable costs of holding such meeting and this solicitation.

Future Outlook

Saba intends to supplement the proxy statement with the date, time, and location of the Special Meeting, as well as the record date and the number of Common Shares outstanding as of the record date.

Management Comments

• We believe the Independent Nominee has an exceptional track record of public company board experience, extensive leadership experience in the finance, mutual fund and closed-end fund industries, including in risk and corporate governance, and we believe she is eminently qualified to serve and would bring a wealth of needed and additive experience to the Fund, especially in the areas of governance and shareholder rights which we believe, as noted further below, have been trampled on by the legacy directors.
• We urge shareholders to approve expanding the Board from four to five members and to appoint the Independent Nominee, who we believe, if appointed as a director of the Fund, would serve the best interests of all shareholders.

Industry Context

Activist investors like Saba Capital often target closed-end funds to address perceived governance issues, undervaluation, or other factors that they believe are detrimental to shareholder value. This proxy fight is part of a broader trend of increased shareholder activism in the investment management industry.

Comparison to Industry Standards

• Poison pills are a common defense mechanism used by companies to prevent hostile takeovers, but their use is controversial and can be viewed as entrenching management at the expense of shareholders.
• The court's ruling against ASA Gold and Precious Metals' poison pill is consistent with legal precedents that limit the duration and scope of such defenses.
• Saba Capital's campaign is similar to other activist campaigns that seek to improve corporate governance and enhance shareholder value.

Legal Proceedings

• Saba Capital filed a complaint in the United States District Court for the Southern District of New York against the Fund, the legacy directors and certain former directors of the Fund seeking rescission of the Poison Pill and a declaratory judgment that the Poison Pill be declared invalid under the 40 Act.
• On March 28, 2025, the Court clearly and unambiguously held that the Poison Pill had been illegally extended beyond the statutory 120-day limit.
• On April 2, 2025, Saba Capital and certain of its affiliates filed a motion with the Court to enforce its ruling invalidating the latest Poison Pill.

Stakeholder Impact

• Shareholders could benefit from improved corporate governance and enhanced shareholder value.
• Employees may be affected by changes in board composition and strategic direction.
• The outcome of the proxy fight could impact the Fund's relationships with its investment manager, administrator, and other service providers.

Next Steps

• Shareholders need to vote on the GOLD proxy card to support the board expansion and the appointment of the independent director.
• Saba Capital will supplement the proxy statement with the date, time, and location of the Special Meeting.
• The Court will rule on Saba Capital's motion to enforce its ruling invalidating the latest Poison Pill.

Key Dates

Keywords

proxy solicitation, board expansion, independent director, Saba Capital, ASA Gold and Precious Metals, poison pill, corporate governance, shareholder rights